Abstract
The synthesis and structure-activity relationships of a novel aryl uracil series which contains a fused 5,6-bicyclic ring unit for HCV NS5B inhibition is described. Several analogs display replicon cell culture potencies in the low nanomolar range along with excellent rat pharmacokinetic values.
Copyright © 2013. Published by Elsevier Ltd.
Publication types
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Bridged Bicyclo Compounds / chemical synthesis
-
Bridged Bicyclo Compounds / chemistry*
-
Bridged Bicyclo Compounds / pharmacokinetics
-
Bridged Bicyclo Compounds / pharmacology*
-
Enzyme Inhibitors / chemical synthesis
-
Enzyme Inhibitors / chemistry*
-
Enzyme Inhibitors / pharmacokinetics
-
Enzyme Inhibitors / pharmacology*
-
Hepacivirus / enzymology
-
RNA-Dependent RNA Polymerase / antagonists & inhibitors
-
RNA-Dependent RNA Polymerase / metabolism
-
Rats
-
Structure-Activity Relationship
-
Uracil / antagonists & inhibitors*
-
Uracil / pharmacology
-
Viral Nonstructural Proteins / antagonists & inhibitors*
-
Viral Nonstructural Proteins / metabolism
Substances
-
Bridged Bicyclo Compounds
-
Enzyme Inhibitors
-
Viral Nonstructural Proteins
-
Uracil
-
NS-5 protein, hepatitis C virus
-
RNA-Dependent RNA Polymerase